Skip to main content

Select Drug Profiles

FDA Approvals, Lung Cancer, Select Drug Profiles

Opdivo-Yervoy First Immunotherapy Combo Approved for First-Line Therapy of Patients with Metastatic NSCLC

FDA Approvals, Select Drug Profiles

Tabrecta First FDA-Approved Targeted Therapy for Metastatic NSCLC and MET Exon 14 Skipping

FDA Approvals, Select Drug Profiles

Retevmo First Therapy Approved for 3 Types of Cancers with RET Mutations

FDA Approvals, Select Drug Profiles

FDA Approves New 400 mg Every-6-Weeks Dosing Regimen of Keytruda for All Indications

FDA Approvals, Select Drug Profiles

Zejula First PARP Inhibitor Approved as First-Line Maintenance Treatment for All Patients with Ovarian Cancer

FDA Approvals, Select Drug Profiles

FDA Approves Darzalex Faspro as Subcutaneous Formulation for All Patients with Multiple Myeloma

FDA Approvals, Urothelial Cancer, Select Drug Profiles

Jelmyto First FDA-Approved Therapy for Low-Grade Upper-Tract Urothelial Cancer

FDA Approvals, Select Drug Profiles

Sarclisa Newest Treatment Approved by the FDA for Patients with Multiple Myeloma

FDA Approvals, In the News, Select Drug Profiles

Tazverik Receives FDA Approval as First Treatment Specifically for Metastatic or Locally Advanced Epithelioid Sarcoma

FDA Approvals, In the News, Select Drug Profiles

Mixed Findings in Annual Cancer Statistics Report

1
2
3
4
5
6
7

Page 4 of 20
Results 31 - 40 of 200